Recurrent Dedifferentiated Liposarcoma
3 clinical trials · Condition
◉ Watch Recurrent Dedifferentiated Liposarcoma
| Record | Firm | Date |
|---|---|---|
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma (NCT05886634) | Memorial Sloan Kettering Cancer Center | 2023-05-23 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (NCT04668300) | M.D. Anderson Cancer Center | 2020-11-26 |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery (NCT03307616) | M.D. Anderson Cancer Center | 2017-10-04 |
Track Recurrent Dedifferentiated Liposarcoma automatically
Every clearance here is in the API, with alerts when new ones post.